Zobrazeno 1 - 10
of 113
pro vyhledávání: ''
Publikováno v:
Annals of Palliative Medicine. 10:8352-8357
An increasing number of anaplastic lymphoma kinase (ALK) gene fusion variants have been reported with the popularity of next-generation sequencing (NGS), such as striatin gene (STRN)-ALK, EMAP like 4 (EML4)-ALK and S1 RNA binding domain 1 (SRBD1)-ALK
Autor:
Chenfei Zhang, Xiao-Dong Zhang, Junji Uchino, Mariano Provencio, Yan Zhang, Tao Li, Yuxian Qian, Yan Wang, Xiang-Rong Shi
Publikováno v:
Translational Lung Cancer Research. 10:1873-1888
Background The effect of anlotinib combined with epidermal growth factor receptor TKIs (EGFR-TKIs) in patients with advanced non-small cell lung cancer (NSCLC) with acquired resistance to EGFR-TKIs and the possible molecular mechanisms are still uncl
Autor:
Jian Hu, Wang Lv, Fei Cheng, Sha Huang, Sijia Yang, Xu Lin, Feichao Bao, Yiqing Wang, Hongxu Sheng, Wenfeng Yu, Xiuwen Tang, Tianyu He
Publikováno v:
Transl Lung Cancer Res
Background The therapeutic efficacy of cisplatin-based chemotherapy for non-small cell lung cancer (NSCLC) is limited by drug resistance. In NSCLC, hyperactivation of nuclear factor erythroid 2-related factor 2 (Nrf2) counteracts oxidative stress to
Publikováno v:
Transl Androl Urol
Renal cell carcinoma (RCC) with anaplastic lymphoma kinase (ALK) rearrangement is rare, and the genetic profiles of the tumor have not been elucidated. Here, we report a case with recurrent papillary RCC and lung metastasis after nephrectomy for near
Autor:
Rong Li, Jin-Bo Huang, Xiao-Dong Zhang, Tao Li, Jun-Guo Lu, Yan Wang, Xiang-Rong Shi, Min-Xin Shi
Publikováno v:
J Thorac Dis
Background High levels of thymidylate synthase (TS) and dihydrofolate reductase (DHFR) expression in tumour tissues are an indicator of ineffective responses to pemetrexed-based chemotherapy in various tumours, including non-small cell lung cancer (N
Autor:
Jillian Wilhelmina Paulina Bracht, Valentina Guarneri, Ana Giménez-Capitán, Carles Codony-Servat, Filippo de Marinis, Giulia Pasello, Miguel Angel Molina-Vila, Rafael Rosell, Pierfranco Conte, Antonio Passaro, Imane Chaib, Matteo Fassan, Alessandro Dal Maso, Jordi Codony-Servat, Erika Aldeguer, Niki Karachaliou, Laura Bonanno, Jordi Berenguer, Ilaria Attili
Publikováno v:
Translational Lung Cancer Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Transl Lung Cancer Res
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Transl Lung Cancer Res
Background: The role of MET alterations in non-small cell lung cancer (NSCLC) is increasing and several targeted agents are under evaluation. MET exon 14 skipping mutations and MET amplifications are associated with potential sensitivity to MET inhib
Autor:
Agnese Cosenza, Cinzia Azzoni, Giuseppe Caruso, Costanza Lagrasta, Roberta Minari, Paola Bordi, Enrico Maria Silini, Leonarda Ferri, Letizia Gnetti, Marcello Tiseo, Lorena Bottarelli, Anna Squadrilli
Publikováno v:
Transl Lung Cancer Res
Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) are the standard treatment for advanced ALK-positive non-small cell lung cancer (NSCLC) allowing survivals up to 5 years. However, duration of responses is limited by the almost certain
Publikováno v:
J Gastrointest Oncol
BACKGROUND: Programmed death-ligand 1 (PD-L1) plays a critical role in host immunity in the setting of cancer progression. Interleukin 10 (IL-10) is a multi-cellular, multi-functional cytokine that regulates cell growth and differentiation and partic
Autor:
Wenjun Peng, Huayin Li, Mengnan Yan, Meijia Chang, Wei Wang, Ge Zhang, Jing Li, Jian Zhou, Chunxue Bai
Publikováno v:
Journal of Thoracic Disease. 12:712-723
Background Tyrosine kinase inhibitors (TKIs), such as gefitinib, are widely used as standard treatments for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. However, the subsequent inevitable drug re
Publikováno v:
Translational Cancer Research
Targeted therapies are validated to be efficient in non-small cell lung cancer (NSCLC) patients with driver gene mutations, but the emergence and development of immune checkpoint inhibitors (ICIs) in the last decades offers new insight into the thera